A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Covid-19
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Participants with increased risk of SARS-CoV-2 infection
    2. Participants who are medically stable such that, according to the judgment of the investigator, hospitalization within the study period is not anticipated and the participant appears likely to be able to remain on study through the end of protocol-specified follow-up
    3. Participants who are able to understand and comply with study requirements/procedures, based on the assessment of the investigator
    4. Female participants of child bearing potential has negative pregnancy test and use acceptable methods of contraception.

You may not be eligible for this study if the following are true:

    1. History of allergy to any component of the vaccine
    2. History of Guillain-Barre´ syndrome or any other demyelinating condition
    3. Significant infection or other acute illness, including fever > 100 °F (> 37.8 °C) on the day prior to or day of randomization
    4. History of laboratory-confirmed SARS-CoV-2 infection
    5. Any confirmed or suspected immunosuppressive or immunodeficient state, including asplenia
    6. Recurrent severe infections and use of immunosuppressant medication
    7. History of primary malignancy
    8. Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture
    9. Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, and neurological illness,
    10. Any other significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data
    11. Pregnant or breastfeeding



If you are registered as a volunteer, please login to the dashboard to send referrals.